- Home
- BWLP vs LQDA Comparison
BWLP vs LQDA Comparison
Compare BWLP & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWLP
- LQDA
- Stock Information
- Founded
- BWLP 1935
- LQDA 2004
- Country
- BWLP Singapore
- LQDA United States
- Employees
- BWLP N/A
- LQDA N/A
- Industry
- BWLP Marine Transportation
- LQDA Biotechnology: Pharmaceutical Preparations
- Sector
- BWLP Consumer Discretionary
- LQDA Health Care
- Exchange
- BWLP Nasdaq
- LQDA Nasdaq
- Market Cap
- BWLP 2.4B
- LQDA 1.9B
- IPO Year
- BWLP N/A
- LQDA 2018
- Fundamental
- Price
- BWLP $12.90
- LQDA $23.15
- Analyst Decision
- BWLP
- LQDA Strong Buy
- Analyst Count
- BWLP 0
- LQDA 9
- Target Price
- BWLP N/A
- LQDA $32.67
- AVG Volume (30 Days)
- BWLP 413.1K
- LQDA 2.1M
- Earning Date
- BWLP 11-27-2025
- LQDA 11-03-2025
- Dividend Yield
- BWLP 10.39%
- LQDA N/A
- EPS Growth
- BWLP N/A
- LQDA N/A
- EPS
- BWLP 1.50
- LQDA N/A
- Revenue
- BWLP $3,554,740,000.00
- LQDA $19,322,000.00
- Revenue This Year
- BWLP N/A
- LQDA $424.31
- Revenue Next Year
- BWLP $3.46
- LQDA $359.32
- P/E Ratio
- BWLP $8.93
- LQDA N/A
- Revenue Growth
- BWLP 1.27
- LQDA 30.20
- 52 Week Low
- BWLP $7.86
- LQDA $9.71
- 52 Week High
- BWLP $16.60
- LQDA $29.94
- Technical
- Relative Strength Index (RSI)
- BWLP 45.26
- LQDA 48.99
- Support Level
- BWLP $12.42
- LQDA $21.97
- Resistance Level
- BWLP $12.87
- LQDA $24.85
- Average True Range (ATR)
- BWLP 0.35
- LQDA 1.26
- MACD
- BWLP 0.09
- LQDA 0.02
- Stochastic Oscillator
- BWLP 72.13
- LQDA 40.98
About BWLP BW LPG Limited Common Shares
BW LPG Ltd is an LPG shipping. It uses pioneering technology to power its vessels with cleaner-burning liquefied petroleum gas (LPG) and invest in R&D to take towards a zero-carbon future. The company is organized into two main segments: The shipping segment and the product services segment which buy and sell liquid petroleum gas and deliver it to customers. It generates the majority of its revenue from the shipping segment.
About LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.